AMGN
Amgen Inc
$366.44
-7.71 (-2.06%)
At close · Jul 6
Market Cap
$197.77B
Shares
539,708,274
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$366.44
Open$371.70
Day$359.47–373.98
52W$266.02–391.29
Avg vol 30d2.7M
Short int12.2M · 2.3% float · 4.1d
Short vol72%
Last earningsApr 30, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 1
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+9% above
+
Price vs 50-day avg
+7% above
◦
RSI (14)
62 · neutral
+
MACD trend
positive
◦
52-week position
80% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $342 › 200d $336 — 50d above 200d
−
Institutional flow
30 of 3,132 funds reported for Jun 30 · net -27.1K sh shares · +2 new
−
Insider flow
Net -$400.5K over 90 days · 100% sells
−
Short interest
2.26% of float · ▲ +2.9% MoM · 4.1 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
3,132 holders — near 3-yr high, broad support
Fundamentals
Strong
+
Revenue growth
+9% Y/Y
+
EPS growth
+88% Y/Y
+
Free cash flow
$8.1B
◦
Valuation
P/E 25.5 · in line
+
Buyback
$6.8B remaining
−
Balance sheet
net debt $49.9B
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Jul 30, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 1, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+9% above
Bullish
Price vs 50-day avg
+7% above
Bullish
RSI (14)
62 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
80% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $342 › 200d $336 — 50d above 200d
Institutional flow
Distributing
30 of 3,132 funds reported for Jun 30 · net -27.1K sh shares · +2 new
Insider flow
Distributing
Net -$400.5K over 90 days · 100% sells
Short interest
Rising
2.26% of float · ▲ +2.9% MoM · 4.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
3,132 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $266
Now $366 · 80%
52-wk high $391
vs 200-day avg +9%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free cash flow non-GAAP | $1.5B | first quarter | — |
| non-GAAP EPS non-GAAP | $5.15 | first quarter | — |
| non-GAAP operating income non-GAAP | $3.7B | first quarter | — |
| non-GAAP operating margin non-GAAP | 45.3% | first quarter | — |
| biosimilar portfolio sales | $835M | first quarter call | — |
| biosimilar portfolio sales growth | 14% | first quarter call | — |
| biosimilars cumulative sales since 2018 | $14B | since 2018 call | — |
| Blincyto sales | $415M | first quarter call | — |
| Blincyto sales growth | 12% | first quarter call | — |
| Eplizna sales | $262M | first quarter call | — |
| Eplizna sales growth | 188% | first quarter call | — |
| Evenity Japan bone builder market share | 55% | first quarter call | — |
| Evenity Japan patients prescribed since launch | 900,000 | since launch call | — |
| Evenity sales | $562M | first quarter call | — |
| Evenity sales growth | 27% | first quarter call | — |
| Evenity U.S. bone builder market share | 65% | first quarter call | — |
| Evenity U.S. patients treated since launch | 320,000 | since launch call | — |
| Imdeltra sales | $258M | first quarter call | — |
| Imdeltra U.S. administering sites | 1,800 | first quarter call | — |
| innovative oncology portfolio sales | $1.8B | first quarter call | — |
| innovative oncology portfolio sales growth | 25% | first quarter call | — |
| key growth drivers sales | $5.6B | first quarter call | — |
| key growth drivers sales growth | 24% | first quarter call | — |
| key growth drivers share of total product sales | 70% | first quarter call | — |
| PABLUE sales | $280M | first quarter call | — |
| Prolia and XGEVA combined sales | $1.1B | first quarter call | — |
| Prolia and XGEVA combined sales change | -32% | first quarter call | — |
| rare disease portfolio sales | $1.2B | first quarter call | — |
| rare disease portfolio sales growth | 25% | first quarter call | — |
| Repatha sales | $876M | first quarter call | — |
| Repatha sales growth | 34% | first quarter call | — |
| TAVNEOS patients treated since launch | 8,000 | since 2021 launch call | — |
| TAVNEOS sales | $119M | first quarter call | — |
| TAVNEOS sales growth | 32% | first quarter call | — |
| TEPEZZA patients treated since launch | 25,000 | since launch call | — |
| TEPEZZA sales | $490M | first quarter call | — |
| TEPEZZA sales growth | 29% | first quarter call | — |
| Test Buyer sales | $343M | first quarter call | — |
| Test Buyer sales growth | 20% | first quarter call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMGN
this stock
Amgen Inc
|
$197.77B | +12.7% | +8.8% | 25.5 | 2.3% |
|
LLY
ELI LILLY & Co
|
$1.13T | +11.9% | +44.7% | 42.6 | 1.0% |
|
JNJ
Johnson & Johnson
|
$633.19B | +27.8% | +6.0% | 30.5 | 1.1% |
|
ABBV
AbbVie Inc.
|
$450.11B | +12.4% | +8.6% | 125.5 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$313.12B | +21.3% | +1.4% | 35.7 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMGN | +2.3% | +6.0% | +13.2% | +1.2% | +12.7% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | -0.8% | +6.8% | +4.9% | +0.6% | +2.6% |
Capital returns
Latest dividend
$2.52
/ share · ex May 15, 2026
Paid (TTM)
$9.80
/ share · 4 payouts
Dividend yield (TTM, derived)
2.67%
Buyback program
· as of Mar 31, 2026
Authorized
$2.40B
Spent (derived)
—
Remaining
$6.80B
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
318154
CUSIP
031162100
13F (30d)
105 filings
45 filers
Visit website
Investor relations